TY - JOUR
T1 - Implications of the LIFE trial
AU - Nadar, Sunil
AU - Lim, Hoong Sern
AU - Lip, Gregory Y.H.
PY - 2003/5/1
Y1 - 2003/5/1
N2 - The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy. This showed that losartan compared to atenolol resulted in a significant reduction in the primary endpoint of cardiovascular morbidity and mortality, as well as a greater reduction in electrocardiographically-defined left ventricular hypertrophy. Importantly, this was despite a mean blood pressure reduction which was similar in both groups. Furthermore, the atenolol arm was associated with higher incidence of newly diagnosed diabetics. The LIFE study has firmly confirmed a place for losartan (and other angiotensin receptor blockers) in the management of hypertension. Losartan has also been shown to be effective in diabetics and in patients with atrial fibrillation, as well as in left ventricular hypertrophy regression. This trial also raises the possibility that β-blockers should perhaps not be used as first-line monotherapy.
AB - The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy. This showed that losartan compared to atenolol resulted in a significant reduction in the primary endpoint of cardiovascular morbidity and mortality, as well as a greater reduction in electrocardiographically-defined left ventricular hypertrophy. Importantly, this was despite a mean blood pressure reduction which was similar in both groups. Furthermore, the atenolol arm was associated with higher incidence of newly diagnosed diabetics. The LIFE study has firmly confirmed a place for losartan (and other angiotensin receptor blockers) in the management of hypertension. Losartan has also been shown to be effective in diabetics and in patients with atrial fibrillation, as well as in left ventricular hypertrophy regression. This trial also raises the possibility that β-blockers should perhaps not be used as first-line monotherapy.
KW - Angiotensin receptor blockers
KW - Cardiovascular mortality
KW - Hypertension
KW - Losartan
UR - http://www.scopus.com/inward/record.url?scp=0038474043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038474043&partnerID=8YFLogxK
U2 - 10.1517/13543784.12.5.871
DO - 10.1517/13543784.12.5.871
M3 - Review article
C2 - 12720497
AN - SCOPUS:0038474043
SN - 1354-3784
VL - 12
SP - 871
EP - 877
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 5
ER -